Approval of Un-audited financial results along with the Limited Review Report for the quarter ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 0.5 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Arunjyoti Bio Ventures approved its Q3 FY26 (Oct-Dec 2025) unaudited financial results on 03 February 2026. Revenue from operations rose to ₹646.82 lakhs from ₹533.65 lakhs in the previous quarter, and the company swung to a small net profit of ₹4.87 lakhs compared to losses of ₹122.73 lakhs in Q2 FY26 and ₹88.76 lakhs in Q3 FY25. On a nine-month basis, revenue declined ~9.2% YoY to ₹2,051.71 lakhs, though net profit improved to ₹86.48 lakhs (from ₹74.90 lakhs). The auditor (PKF Sridhar & Santhanam LLP) issued an unmodified review report but included an emphasis of matter on restated comparatives related to a deferred tax correction, and noted that prior periods were reviewed by a predecessor auditor, indicating a recent auditor change.
The sequential turnaround to profit is a positive signal, but the 9-month revenue contraction and the restatement of prior figures (along with a change in auditor) may raise governance and consistency concerns for shareholders. Investors should watch whether the Q3 recovery sustains and whether revenue growth resumes in the coming quarters.